The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Theranostic Applications of Nanomaterials in Cancer: Drug Delivery, Image-Guided Therapy, and Multifunctional Platforms
Open accessAbstract
Successful cancer management depends on accurate diagnostics along with specific treatment protocols. Current diagnostic techniques need to be improved to provide earlier detection capabilities, and traditional chemotherapy approaches to cancer treatment are limited by lack of specificity and systemic toxicity. This review highlights advances in nanotechnology that have allowed the development of multifunctional platforms for cancer detection, therapy, and monitoring. Nanomaterials can be used as MRI, optical imaging, and photoacoustic imaging contrast agents. When used as drug carriers, nanoformulations can increase tumor exposure to therapeutic agents and result in improved treatment effects by prolonging circulation times, protecting entrapped drugs from degradation, and enhancing tumor uptake through the enhanced permeability and retention effect as well as receptor-mediated endocytosis. Multiple therapeutic agents such as chemotherapy, antiangiogenic, or gene therapy agents can be simultaneously delivered by nanocarriers to tumor sites to enhance the effectiveness of therapy. Additionally, imaging and therapy agents can be co-delivered to provide seamless integration of diagnostics, therapy, and follow-up, and different therapeutic modalities such as chemotherapy and hyperthermia can be co-administered to take advantage of synergistic effects. Liposomes, metallic nanoparticles, polymeric nanoparticles, dendrimers, carbon nanotubes, and quantum dots are examples of nanoformulations that can be used as multifunctional platforms for cancer theranostics. Nanomedicine approaches in cancer have great potential for clinically translatable advances that can positively impact the overall diagnostic and therapeutic process and result in enhanced quality of life for cancer patients. However, a concerted scientific effort is still necessary to fully explore long-term risks, effects, and precautions for safe human use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Biodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00048-3 · Cited by 2,617
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623
Cho, H.-S., Dong, Z., Pauletti, G. M., Zhang, J., Xu, H., Gu, H., Wang, L., Ewing, R. C., Huth, C., Wang, F., et al. (2010) · ACS Nano · doi:10.1021/nn101000e · Cited by 265
Jain, A. K., Swarnakar, N. K., Godugu, C., Singh, R. P., & Jain, S. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.09.037 · Cited by 232
Xu, J. S., Huang, J., Qin, R., Hinkle, G. H., Povoski, S. P., Martin, E. W., & Xu, R. X. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.052 · Cited by 108
Cited by
Polylactic acid (PLA) controlled delivery carriers for biomedical applications
Tyler, B., Gullotti, D., Mangraviti, A., Utsuki, T., & Brem, H. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.018 · Cited by 1,050
Meng, W., He, C., Hao, Y., Wang, L., Li, L., & Zhu, G. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1748758 · Cited by 592
Mesoporous Silica Nanoparticles for Drug Delivery: Current Insights
Vallet-Regí, M., Colilla, M., Izquierdo-Barba, I., & Manzano, M. (2017) · Molecules · doi:10.3390/molecules23010047 · Cited by 538
Nanotheranostics for personalized medicine
Mura, S., & Couvreur, P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.06.006 · Cited by 527
Targeted therapy using nanotechnology: focus on cancer
Sechi, M., Sanna, V., & Pala, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s36654 · Cited by 493
Metadata
- Authors
- Fernandez-Fernandez, A., Manchanda, R., & McGoron, A. J.
- Venue
- Applied Biochemistry and Biotechnology
- Published
- 2011-09-27
- Volume
- 165
- Issue
- 7-8
- Pages
- 1628-1651
- ISSN
- 0273-2289 (ISSN-L)
- 1559-0291
- OpenAlex
- W2043962829
- Cited by
- 330
- References
- 6
- FWCI
- 14.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Theranostic Applications of Nanomaterials in Cancer: Drug Delivery, Image-Guided Therapy, and Multifunctional Platforms. https://app.cochat.ai/papers/10.1007/s12010-011-9383-z
- The paper
- Fernandez-Fernandez, A., Manchanda, R., & McGoron, A. J. (2011). Theranostic Applications of Nanomaterials in Cancer: Drug Delivery, Image-Guided Therapy, and Multifunctional Platforms. Applied Biochemistry and Biotechnology. https://doi.org/10.1007/s12010-011-9383-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.